Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

I received this morning, at 6:00 European time, an alert that the 23-Feb-2021 Press Release on the NeuroRX site had been updated.

Here is the new title of that Press Release :

-------------------------------------
NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28-Day Interim Endpoint
-------------------------------------

and here below is the updated part of the 23-Feb-2021 Press Release - very different POSITIVE language which shows a massive 46% improvement at Day 28 :

==========================
At 28 days, patients treated with ZYESAMI™ demonstrate 35% higher likelihood of recovery from respiratory failure with continued survival compared to patients treated with placebo (Hazard Ratio 1.53; P=.08). In tertiary care hospitals, ZYESAMI-treated patients were 46% more likely to recover and return home before day 28 (Hazard Ratio controlling for age and severity 1.84; P=.058). Should these trends continue through day 60, they have the potential to reach statistical significance. At day 28, a highly significant 10-day difference in median time to recovery and hospital discharge has emerged in ZYESAMI-treated patients compared to those treated with placebo (P<.006).
==========================

Ilka ~ from Y@h00 Rlftf conversations

https://www.neurorxpharma.com/latest-news/